- Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission.- In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24.- EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported.SHANGHAI, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK,“Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. In an analysis of the data available as of September 13th, 2024, results from the Phase 1b/2a clinical trial showed that for patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission1 and 10 out of 11 (91%) achieved immunological complete remission (ICR)2. In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved ICR by week 24.EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of autoimmune renal diseases. Compared to covalent irreversible BTK inhibitors, EVER001 offers improved selectivity while maintaining high potency, thereby potentially avoiding many of the side effects associated with earlier-generation BTK inhibitors. Everest Medicines holds global rights to EVER001 for the treatment of renal diseases.The Phase 1b/2a clinical trial of EVER001 for the treatment of pMN is an ongoing trial conducted in China. A total of 31 patients with biopsy-proven pMN who tested positive for anti-PLA2R autoantibodies were enrolled into two cohorts. The total treatment duration was 36 weeks. Based on the patient data collected by September 13th, 2024, in the low-dose cohort, the geometric least squares mean 24-hour proteinuria decreased by 78.3% at week 36 compared to baseline, while the high-dose cohort achieved a 73.8% reduction by week 24. EVER001 treatment induced greater than 90% reductions in anti-PLA2R antibody as early as week 24 in the low-dose cohort and week 12 in the high-dose cohort. EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported."We are excited to see the encouraging results in this preliminary analysis of our Phase 1b/2a clinical proof-of-concept trial of EVER001. This demonstrates the potential of EVER001 as a next-generation BTK inhibitor for the treatment of various autoimmune renal diseases, including pMN. "Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said："This data release marks the first time Everest Medicines has disclosed results from its global pipeline. We look forward to completing this trial and sharing detailed data in future conferences and publications. Moving forward, we will continue to drive the global clinical development of EVER001, to meet patients' urgent clinical needs.”Membranous nephropathy is a common pathological type of nephrotic syndrome in adults, and its prevalence in China has been increasing, ranking second only to IgA nephropathy3. There are about 2 million patients with pMN in China, with an estimated 80,000 to 100,000 patients in the United States, 80,000 in Europe, and 40,000 in Japan. There are no approved drugs for this indication worldwide. The current treatment goal is to improve remission rates, reduce high relapse rates, and minimize the risk of chronic toxicity caused by currently available treatments. More than one-third of pMN patients still progress to end-stage renal disease under current standards of care.This Phase 1b/2a clinical trial was approved by the Center for Drug Evaluation of the National Medical Products Administration in September 2022 to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EVER001 in Chinese patients with glomerular diseases characterized by proteinuria. The previously published results of a Phase 1 study conducted in healthy Chinese and Australian subjects conducted by SinoMab BioScience indicate that EVER001 has high selectivity, excellent pharmacokinetic properties, a good safety profile, and strong target binding.About EVER001EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 trial with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, strong target binding and a safety profile that supports continued clinical development.Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases.Investor Calls InformationEverest Medicines will hold investor calls on the data results from EVER001 Phase 1b/2a clinical study in primary membranous nephropathy. EVER001 is a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, and Everest owns the global rights to develop EVER001 for the treatment of renal diseases.The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024, Beijing Time (8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (9:30 PM U.S. Eastern Time on Dec. 3, 2024).The conference calls can be accessed by the following links:For English Session:Time: 9:00 AM Beijing Time, Wednesday, Dec. 4, 2024 (8:00 PM U.S. Eastern Time on Dec. 3, 2024)Pre-Registration Link: https://www.acecamptech.com/eventDetail/60510700Webcast Link:https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700Alternatively, participants may dial in to the conference call using below dial-in information:United States: +1-646-2543594 (EN)Chinese Mainland: +86-10-58084166 (EN), +86-10-58084199 (CN)Hong Kong, China: +852-30051313 (EN), +852-30051355 (CN)United Kingdom: +44-12-1368-0466 (EN)International: +1-866-6363243 (EN)Password: 842080For Mandarin Session:Time: 10:30 AM Beijing Time, Wednesday, Dec. 4, 2024 (9:30 PM U.S. Eastern Time on Dec. 3, 2024)Webcast Link: https://s.comein.cn/n3arj55sAlternatively, participants may dial into the conference call using below dial-in information:United States: +1-646-3578788, +1-408-7093255Chinese Mainland: 400-969-8928, 400-806-3263Hong Kong, China: +852-301-83602Taiwan, China: +886-226563394, +886-277417882Singapore: +65-64075649, +65-66220840United Kingdom: +44-2070970018 International: +86-2362737123Password: 377570The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at http://www.everestmedicines.com.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.References:1.Overall clinical remission (complete remission or partial remission): 24h proteinuria complete remission (CR): 24h proteinuria < 0.3g/24 h; 24h proteinuria partial remission (PR): 24h proteinuria < 3.5g/24h, but ≥0.3g/24 h, and reduction > 50%, regardless of eGFR or the serum albumin level from baseline.2. Immunological complete remission (ICR): anti-PLA2R titer < 20RU/ml (negative).3. Expert consensus on the application of rituximab in the treatment of membranous nephropathy, Chin J Intern Med, March 2022, Vol. 61, No. 3. Copyright 2024 ACN Newswire via SeaPRwire.com.

- 在已完成36周治疗的低剂量组患者中，81.8%（9/11）的患者实现临床缓解，高剂量组中已完成24周治疗的患者已有85.7%（6/7）实现临床缓解。- 除低剂量组的1例患者外，其他所有完成36周治疗的低剂量组患者，以及所有经24周治疗的高剂量组患者分别在36周和24周都实现了免疫学完全缓解。- EVER001总体安全性和耐受性良好。未见在其他共价非可逆BTK抑制剂上观察到的有临床意义的不良事件，如出血、心律失常、严重感染、白细胞减少、血小板减少、严重肝功能损伤等。上海, 2024年12月4日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布新一代共价可逆布鲁顿酪氨酸激酶（BTK）抑制剂 EVER001胶囊（又名：XNW1011）在治疗原发性膜性肾病（primary membranous nephropathy，pMN）的1b/2a期临床试验阶段性数据取得积极结果。直至9月13日的数据截止日期，结果显示，在已完成36周治疗的低剂量组患者中，81.8%（9/11）的患者实现临床缓解，高剂量组中已完成24周治疗的患者已有85.7%（6/7）实现临床缓解。除低剂量组的1例患者外，其他所有完成36周治疗的低剂量组患者，以及所有经24周治疗的高剂量组患者分别在36周和24周都实现了免疫学完全缓解。EVER001是一款适用于自身免疫性肾脏疾病的共价可逆BTK抑制剂。与共价不可逆BTK抑制剂相比，EVER001作为一款潜在的同类最佳产品，在保持高活性的同时具有高选择性，避免持续抑制带来的毒副作用。云顶新耀拥有这款产品用于肾病治疗的全球权益。EVER001治疗原发性膜性肾病的1b/2a期临床试验为一项正在进行中的中国研究。共有31名经肾脏活检证实的抗-PLA2R自身抗体阳性的原发性膜性肾病患者分别入组低剂量组和高剂量组，接受EVER001 共36周的治疗。截至2024年9月13日的数据分析，低剂量组的24小时蛋白尿几何平均值（最小二乘法）在36周相较于基线下降78.3%，而高剂量组在24周即出现73.8%的下降。抗-PLA2R自身抗体水平在数据截止日期时已达到接近100%的下降，而早在低剂量组的24周和高剂量组的12周，抗-PLA2R自身抗体下降已超过90%。EVER001总体安全性和耐受性良好。未见在其他共价非可逆BTK抑制剂上观察到的有临床意义的不良事件，如出血、心律失常、严重感染、白细胞减少、血小板减少、严重肝功能损伤等。云顶新耀首席执行官罗永庆表示："非常高兴看到EVER001在此次公布的阶段性数据中取得了积极的结果。这显示了EVER001作为新一代BTK抑制剂，对包括原发性膜性肾病在内的多种自身免疫性肾病治疗的巨大潜力。迄今为止，全球没有获批原发性膜性肾病适应症的药物。作为首个公布的具有全球权益的管线产品数据，EVER001在原发性膜性肾病患者中取得的阶段性结果令人鼓舞。我们也期待该1b/2a期临床试验的完成及更多相关数据的发表。我们将继续推进EVER001的全球临床开发，以最快速度满足患者的临床需求。"膜性肾病为成人肾病综合征常见的病理类型，在我国的患病率呈逐年升高的趋势，是发病率仅次于IgA肾病的原发性肾小球肾炎1。我国目前有约200万原发性膜性肾病患者，而在美国约有8万-10万患者，欧洲约8万患者，日本约4万患者。目前全球没有获批此适应症的药物。超过1/3的原发性膜性肾病患者最终将进展为终末期肾病，全球亟需研发能提高治疗缓解率、降低高复发率、减少慢性肾毒性风险的治疗药物。此项1b/2a期临床试验于2022年9月获得中国国家药品监督管理局药品审评中心批准，用于评价EVER001在蛋白尿为特征的肾小球疾病的中国患者中的安全性、疗效、药代动力学和药效学。此前公布的中国抗体制药在中国健康受试者中进行的1期研究结果表明，EVER001具有高选择性、优异的药代动力学特征、良好的安全性特征以及强大的靶点结合力。关于EVER001EVER001胶囊（又名：XNW1011）是新一代共价可逆的布鲁顿酪氨酸激酶 （BTK）抑制剂，正在全球范围内开发用于治疗肾病。BTK是B 细胞受体信号通路的重要组成部分，可调节 B 淋巴细胞的存活、激活、增殖和分化。应用小分子抑制剂靶向 BTK 是治疗 B 细胞淋巴瘤和自身免疫性疾病的有效选择。中国抗体制药在国内完成的健康受试者I期研究结果表明，EVER001具有高选择性、优异的药代动力学特征、强大靶点结合力和良好的安全性特征，研究结果支持其进一步临床开发。根据与信诺维医药和中国抗体制药的独家许可协议，云顶新耀拥有在全球开发、生产和商业化EVER001用于治疗肾病的权利。投资人会议公司将举行中英文投资人线上会议，公布新一代共价可逆布鲁顿酪氨酸激酶（BTK）抑制剂 EVER001胶囊治疗原发性膜性肾病的1b/2a期临床试验数据。云顶新耀拥有EVER001在全球范围内开发用于治疗肾病领域的权益。英文场次将于北京时间2024年12月4日上午9时（美国东部时间12月3日晚上8时）举行；中文场次将于北京时间同日上午10:30时（美国东部时间12月3日晚上9:30时）举行。英文会议：会议时间：北京时间2024年12月4日，星期三，上午9时（美国东部时间12月3日晚上8时）提前注册链接：https://www.acecamptech.com/eventDetail/60510700会议直播链接：https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700同时，参会者也可以使用以下拨入信息拨入电话会议：美国：+1-646-2543594 (EN)中国大陆：+86-10-58084166 (EN)，+86-10-58084199 (CN)中国香港：+852-30051313 (EN)，+852-30051355 (CN)英国：+44-12-1368-0466 (EN)国际：+1-866-6363243 (EN)会议代码：842080中文会议：会议时间：北京时间2024年12月4日，星期三，上午10:30时（美国东部时间12月3日晚上9:30时）会议直播链接： https://s.comein.cn/n3arj55s同时，参会者也可以使用以下拨入信息拨入电话会议：美国:+1-646-3578788，+1-408-7093255中国大陆:400-969-8928，400-806-3263中国香港:+852-301-83602中国台湾:+886-226563394，+886-277417882新加坡:+65-64075649，+65-66220840英国:+44-2070970018海外:+86-2362737123会议密码:377570英文会议结束后，您可以通过访问云顶新耀官网（http://www.everestmedicines.com）收听英文会议回放。关于云顶新耀云顶新耀是一家专注于创新药和疫苗研发、临床开发、制造和商业化的生物制药公司，致力于满足亚洲市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业从事过高质量研发、临床开发、药政事务、化学制造与控制（CMC）、业务发展和商业化运营，拥有深厚的专长和丰富的经验。云顶新耀已打造多款疾病首创或者同类最佳的药物组合，公司的治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。有关更多信息，请访问公司网站：www.everestmedicines.com。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。参考文献：1.利妥昔单抗在膜性肾病中应用的专家共识，中华内科杂志2022年3月第61卷第3期。 Copyright 2024 亚太商讯 via SeaPRwire.com.

TSUKUBA, Japan, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Polymers, such as plastics, are essential in many aspects of life and industry, from packaging and cars to medical devices and optic fibres. Their value comes from diverse properties that are largely determined by their monomers – the single chemical units – that make up a polymer. Unfortunately, it can be challenging to control the chemical behaviour of monomers during manufacture to achieve a desired outcome.The flow synthesis reactor with two bottles containing a monomer, initiator and solvent mixed using a micromixer. The synthesis is controlled with AI-based design of experimental conditions such as the temperature and a flow rate. Now, a team of researchers led by Professor Mikiya Fujii of the Nara Institute of Science and Technology in Japan have used machine learning to mathematically model the polymerization process and reduce the need for time-consuming and expensive experimentation. Their results have been published in the journal Science and Technology of Advanced Materials: Methods.Machine learning algorithms need data, so the researchers designed a polymerization process that would quickly and efficiently generate experimental data to feed into the mathematical model. The target molecule was a styrene-methyl methacrylate co-polymer, which was made by mixing styrene and methyl methacrylate monomers, both already dissolved in a solvent with an added initiator substance, then heating them in a water bath.The team also used a method called flow synthesis, in which the two monomer solutions are mixed and heated in a constant flow. This allows for better mixing, more efficient heating, and more precise control of heating time and flow rate, which makes it ideal for use with machine learning.The modelling evaluated the effect of five key variables in the polymerization process: the concentration of the initiator, the ratio of solvent to monomer, the proportion of styrene, the temperature of the reaction, and the time spent in the water bath. The goal was to have an end product with as close to 50% styrene as possible.Once enough experimental data was available, the machine learning process took only five cycles of calculation to achieve the ideal proportion of styrene to methyl methacrylate. The results showed that the key was a lower temperature and longer time in the water bath, as well as lowering the relative concentration of the monomer in the solvent. The researchers were surprised to discover that the solvent concentration was just as important as the proportion of monomers going into the mix.“Our results demonstrate that machine learning not only can explicitly reveal what humans may have implicitly taken for granted but can also provide new insights that weren’t recognized before,” Professor Mikiya Fujii says. “The use of machine learning in chemistry could open the door for smarter, greener manufacturing processes with reduced waste and energy consumption.”Further informationMikiya FujiiNara Institute of Science and TechnologyEmail: fujii.mikiya@ms.naist.jp Paper: https://doi.org/10.1080/27660400.2024.2425178About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-M Dr Yasufumi NakamichiSTAM Publishing DirectorEmail: NAKAMICHI.Yasufumi@nims.go.jp Press release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - OKX, the leading cryptocurrency exchange, has partnered with DeAgentAI, the first AI-driven feedback incentive protocol in Web3, to launch an exclusive airdrop campaign. Starting December 3rd, users can complete simple tasks on OKX Wallet to win a share of $50,000 worth of DA tokens.Click here to join the campaign: https://www.okx.com/web3/giveawayParticipating in the DeAgentAI and OKX Wallet airdrop is easy. Download the OKX Wallet, follow DeAgentAI social media networks, and complete a few simple tasks such as sharing campaign posts, and you can claim your rewards. The campaign runs from December 3rd for two weeks-don't miss out!This collaboration brings users unparalleled opportunities to explore advanced AI technology while enjoying the benefits of a secure and user-friendly wallet. With rewards of $50,000 worth of DA tokens, the initiative encourages users to explore Web3 in an innovative and incentivized environment. DeAgentAI and OKX Wallet aim to foster adoption and empower users in the rapidly evolving crypto space.About DeAgentAIDeAgentAI is a trailblazer in Web3 technology, introducing the first AI feedback mechanism incentive protocol that achieves "proof of insight" by integrating user feedback into the model training process. Its flagship product, AlphaX, combines advanced MOE and Transformer architectures to predict BTC and ETH price trends with over 80% accuracy.What is OKX's Web3 Wallet?OKX Wallet complements this innovation with its secure and user-friendly interface tailored for decentralized finance (DeFi) and Web3 applications. As a leading wallet in the crypto space, OKX Wallet enables seamless integration with platforms like DeAgentAI, empowering users to engage in token giveaways, explore cutting-edge AI tools, and participate in the rapidly growing Web3 ecosystem.Contact InformationYves-Alexandre d'OuradouFounderdeagent.ai@gmail.com(001) 2024989991Source: DeAgentAI Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - The Japan Maritime Self-Defense Force (JMSDF) has selected the General Atomics Aeronautical Systems, Inc. (GA-ASI) SeaGuardian® Remotely Piloted Aircraft (RPA) systems for its Long Endurance Unmanned Aerial Vehicle program. This follows JMSDF use of SeaGuardian since May 2023 as part of its Medium-Altitude, Long Endurance (MALE) RPA System Trial Operations Project.SeaGuardian has been used by JMSDF to conduct various tests including whether unmanned aircraft can supplant some of the missions currently accomplished with manned aircraft. SeaGuardian is a MALE RPA system that can fly for 24 hours or more, depending on the configuration.GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its Intelligence, Surveillance and Reconnaissance (ISR) information in real time. GA-ASI's Optix+ software suite rapidly correlates and exploits collected data into an easily shared common operational picture. Having multi-source correlated data enables automatic detection of anomalous behaviors over waters.SeaGuardian features two multi-mode maritime surface-search radars with an Inverse Synthetic Aperture Radar (ISAR) imaging mode, an Automatic Identification System (AIS) receiver, and a High-Definition - Full-Motion Video sensor equipped with optical and infrared cameras as well as electronic intelligence receivers. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles and provides automatic tracking of maritime targets and correlation of AIS transmitters with radar and electronic intelligence tracks.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com .Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - December 3, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") a leading North American exploration company focused on critical minerals, acknowledges today's announcement by China banning exports of gallium, germanium, and antimony to the United States. This move underscores the urgent need for Western nations to secure reliable long-term sources of these essential materials.Antimony, a critical component in military applications, energy storage, and advanced manufacturing, is now at the forefront of the global supply chain crisis. China's ban, coupled with existing restrictions that came into effect September 15, 2024, has already sent antimony prices soaring by over 228% this year(1). The Western world faces mounting pressure to address its reliance on China for strategic resources critical to national defense and technological innovation. This ban comes at a time when defense sector inventories are at already concerningly low levels.(2)Military Metals recent antimony mineral project acquisitions in Slovakia, Nova Scotia, and Nevada provide shareholders with a pure antimony play with a diverse portfolio in top jurisdictions."This announcement from China reinforces the importance of Military Metals' mission to secure a sustainable, independent future supply chain for critical minerals," said Scott Eldridge, CEO of Military Metals Corp. "The West can no longer afford to rely on adversarial nations for resources essential to our security and economic stability. We are taking proactive steps to meet this growing demand with future domestic and allied sources of antimony."As geopolitical tensions escalate and the trade war intensifies, Military Metals will continue to prioritize the development of critical mineral resources and work closely with governments and industry partners to ensure the West remains resilient and self-sufficient.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release include exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties.. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.(1)Reuters; China bans export of critical minerals to US as trade tensions escalate; By Amy Lv and Tony Munroe; December 3, 2024(2)Heritage Foundation: commentary/It’s Past Time to Re-Supply Our Munitions-Depleted U.S. Navy by Jim Fein; June 17, 2024To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232325 Copyright 2024 ACN Newswire via SeaPRwire.com.